A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China

Inclusion Criteria: 1. Willingness to provide written informed consent for the study. 2. Male or female subjects, age 18-45 years older. 3. Within body mass index (BMI) range 19.0 to 26.0 kilograms per square meter (kg/m²). 4. The results of vital signs, physical examination, laboratory tests, electrocardiogram, chest X-ray and other examinations during the screening period are normal or judged to be abnormal by the investigator and have no clinical significance. 5. Males and females of non-childbearing potential. Exclusion Criteria: 1. History of severe allergies or allergies to 611 and any of its components; 2. Previous or current disease that may affect the safety of the subject's participation in the trial or the in vivo process of the trial drug; 3. Any history of VKC and AKC; 4. History of drug abuse within 2 years prior to screening; 5. Alcoholism within 3 months prior to screening; 6. Those who smoke more than 5 cigarettes per day within 3 months before screening or cannot give up smoking during the period from signing the informed consent of the subject to leaving the group; 7. Those who have consumed more than 1L of strong tea, coffee and/or caffeinated beverages per day within 3 months before screening, and who have ingested chocolate or any food or drink containing caffeine, theophylline, theobromine or alcohol within 48 hours before the study administration; 8. Have active tuberculosis; 9. Presence of active infection requiring systemic treatment prior to screening or dosing; 10. Those who have used any prescription drugs, over-the-counter drugs, vitamin products or Chinese herbal medicines within 4 weeks or 5 half lives (whichever is longer) before dosing, or those who may need to receive other drugs during the trial; 11. Participated in the clinical trial of any drug or device within 3 months or 5 half-lives before dosing; 12. Receipt of any marketed or investigational biologic within 3 months or 5 half lives prior to dosing; 13. Live vaccine or live attenuated vaccine within 2 months prior to dosing or planned administration during the study; 14. Previous use of any IL-4Rα target drugs; 15. Pregnant or lactating females;